JP7714811B2 - １，３，４，７－テトラヒドロ－２Ｈ－ピロロ［３’，２’：５，６］ピリド［２，３－Ｂ］［１，４］オキサアゼピンＢｃｌ－２阻害剤 - Google Patents

１，３，４，７－テトラヒドロ－２Ｈ－ピロロ［３’，２’：５，６］ピリド［２，３－Ｂ］［１，４］オキサアゼピンＢｃｌ－２阻害剤

Info

Publication number
JP7714811B2
JP7714811B2 JP2024540933A JP2024540933A JP7714811B2 JP 7714811 B2 JP7714811 B2 JP 7714811B2 JP 2024540933 A JP2024540933 A JP 2024540933A JP 2024540933 A JP2024540933 A JP 2024540933A JP 7714811 B2 JP7714811 B2 JP 7714811B2
Authority
JP
Japan
Prior art keywords
stirred
added
solution
methyl
title compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2024540933A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025504382A5 (https=
JPWO2023141536A5 (https=
JP2025504382A (ja
Inventor
ドハーティ，ジョージ・エイ
バート，ビクラム
ブレイディ，パトリック
ダイ，ユージア
ゴング，ジアンチュン
ジャッド，アンドリュー・エス
サワーズ，アンドリュー・ジェイ
ユー，イーユン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of JP2025504382A publication Critical patent/JP2025504382A/ja
Publication of JP2025504382A5 publication Critical patent/JP2025504382A5/ja
Publication of JPWO2023141536A5 publication Critical patent/JPWO2023141536A5/ja
Priority to JP2025118767A priority Critical patent/JP2025160251A/ja
Application granted granted Critical
Publication of JP7714811B2 publication Critical patent/JP7714811B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2024540933A 2022-01-21 2023-01-20 １，３，４，７－テトラヒドロ－２Ｈ－ピロロ［３’，２’：５，６］ピリド［２，３－Ｂ］［１，４］オキサアゼピンＢｃｌ－２阻害剤 Active JP7714811B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025118767A JP2025160251A (ja) 2022-01-21 2025-07-15 １，３，４，７－テトラヒドロ－２Ｈ－ピロロ［３’，２’：５，６］ピリド［２，３－Ｂ］［１，４］オキサアゼピンＢｃｌ－２阻害剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263267018P 2022-01-21 2022-01-21
US63/267,018 2022-01-21
PCT/US2023/060944 WO2023141536A1 (en) 2022-01-21 2023-01-20 1,3,4,7-tetrahydro-2h-pyrrolo [3',2':5,6] pyrido[2,3-b] [1,4] oxazepine bc1-2 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025118767A Division JP2025160251A (ja) 2022-01-21 2025-07-15 １，３，４，７－テトラヒドロ－２Ｈ－ピロロ［３’，２’：５，６］ピリド［２，３－Ｂ］［１，４］オキサアゼピンＢｃｌ－２阻害剤

Publications (4)

Publication Number Publication Date
JP2025504382A JP2025504382A (ja) 2025-02-12
JP2025504382A5 JP2025504382A5 (https=) 2025-06-09
JPWO2023141536A5 JPWO2023141536A5 (https=) 2025-06-09
JP7714811B2 true JP7714811B2 (ja) 2025-07-29

Family

ID=85382827

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024540933A Active JP7714811B2 (ja) 2022-01-21 2023-01-20 １，３，４，７－テトラヒドロ－２Ｈ－ピロロ［３’，２’：５，６］ピリド［２，３－Ｂ］［１，４］オキサアゼピンＢｃｌ－２阻害剤
JP2025118767A Pending JP2025160251A (ja) 2022-01-21 2025-07-15 １，３，４，７－テトラヒドロ－２Ｈ－ピロロ［３’，２’：５，６］ピリド［２，３－Ｂ］［１，４］オキサアゼピンＢｃｌ－２阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025118767A Pending JP2025160251A (ja) 2022-01-21 2025-07-15 １，３，４，７－テトラヒドロ－２Ｈ－ピロロ［３’，２’：５，６］ピリド［２，３－Ｂ］［１，４］オキサアゼピンＢｃｌ－２阻害剤

Country Status (13)

Country Link
US (3) US11964990B2 (https=)
EP (1) EP4466273A1 (https=)
JP (2) JP7714811B2 (https=)
KR (1) KR20240136972A (https=)
CN (1) CN119053610A (https=)
AR (1) AR128310A1 (https=)
AU (1) AU2023210279A1 (https=)
CA (1) CA3242074A1 (https=)
CO (1) CO2024009334A2 (https=)
IL (1) IL312709A (https=)
MX (1) MX2024008840A (https=)
TW (1) TW202340210A (https=)
WO (1) WO2023141536A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11964990B2 (en) * 2022-01-21 2024-04-23 Abbvie Inc. 1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors
CN117820134A (zh) * 2024-01-10 2024-04-05 山东盛安贝新材料有限公司南京分公司 一种顺式-3-甲氧基环丁胺盐酸盐的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019040550A1 (en) 2017-08-23 2019-02-28 Newave Pharmaceutical Inc. CONDENSED HETEROCYCLIC DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12220419B2 (en) 2018-08-22 2025-02-11 Newave Pharmaceutical Inc. BCL-2 inhibitors
WO2020140005A2 (en) 2018-12-29 2020-07-02 Newave Pharmaceutical Inc. Bcl-2 inhibitors
WO2021066873A1 (en) 2019-10-03 2021-04-08 Newave Pharmaceutical Inc. Condensed heterocycles as bcl-2 inhibitors
WO2021083135A1 (en) 2019-10-28 2021-05-06 Beigene, Ltd. Bcl-2 INHIBITORS
WO2021133817A1 (en) 2019-12-27 2021-07-01 Guangzhou Lupeng Pharmaceutical Company Ltd. 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases
KR20220158725A (ko) 2020-02-24 2022-12-01 광조우 루펭 파마슈티칼 컴퍼니 엘티디. Bcl2 억제제를 함유하는 핫 멜트 압출 고체 분산체
US11964990B2 (en) * 2022-01-21 2024-04-23 Abbvie Inc. 1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019040550A1 (en) 2017-08-23 2019-02-28 Newave Pharmaceutical Inc. CONDENSED HETEROCYCLIC DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES

Also Published As

Publication number Publication date
KR20240136972A (ko) 2024-09-19
WO2023141536A1 (en) 2023-07-27
US11964990B2 (en) 2024-04-23
IL312709A (en) 2024-07-01
CN119053610A (zh) 2024-11-29
CO2024009334A2 (es) 2024-07-18
JP2025160251A (ja) 2025-10-22
AR128310A1 (es) 2024-04-17
AU2023210279A1 (en) 2024-05-23
US20250066388A1 (en) 2025-02-27
US20260028356A1 (en) 2026-01-29
EP4466273A1 (en) 2024-11-27
JP2025504382A (ja) 2025-02-12
MX2024008840A (es) 2024-07-25
TW202340210A (zh) 2023-10-16
US20230234971A1 (en) 2023-07-27
CA3242074A1 (en) 2023-07-27

Similar Documents

Publication Publication Date Title
JP2025160251A (ja) １，３，４，７－テトラヒドロ－２Ｈ－ピロロ［３’，２’：５，６］ピリド［２，３－Ｂ］［１，４］オキサアゼピンＢｃｌ－２阻害剤
CA2909620C (en) Staple and suture polypeptides and their uses
CN112969683A (zh) O-取代的丝氨酸衍生物制备方法
TW201920194A (zh) 大環ｍｃｌ-１抑制劑及使用方法
WO2010084798A1 (ja) ３環性化合物
CN117677627A (zh) 分拣蛋白活性调节剂
WO2015172732A1 (zh) 作为二肽基肽酶-iv抑制剂的氨基四氢吡喃衍生物
JP2024540163A (ja) Ｒｘｆｐ１アゴニスト
JP2024540164A (ja) Ｒｘｆｐ１アゴニスト
KR20240099355A (ko) Rxfp1 효능제
KR20160067840A (ko) 펩티드-올리고우레아 키메라 화합물 및 이의 사용 방법
JPH06501681A (ja) レトロウイルス・プロテアーゼの阻害剤
ES2634693T3 (es) Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil¿oxazol como agonistas del receptor de ALX
US20050113397A1 (en) Imidazo[1,2-a]pyridine derivative
WO2023196429A1 (en) Modulators of cystic fibrosis transmembrane conductance regulator
CN105008369B (zh) 人类免疫缺陷病毒复制抑制剂
IL324629A (en) Cyclin inhibitors
JPWO2016143699A1 (ja) ジピリンホウ素錯体及びこれを含有する医薬
EP3070086B1 (en) Azaindole derivative
JP2020533374A (ja) 環状ペプチド抗生物質
CA3136351C (en) Benzimidazole derivatives and their uses
WO2026022218A1 (en) Proteasome inhibitors
CN118974059A (zh) 囊性纤维化跨膜传导调控因子的调节剂
WO2021098817A1 (zh) 二氧代哌嗪类衍生物、其制备方法及其在医药上的应用
US20250215010A1 (en) Diazabicyclooctane derivatives useful as matrix metalloproteinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250530

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250530

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250530

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250617

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250716

R150 Certificate of patent or registration of utility model

Ref document number: 7714811

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150